Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Modular PMA policy tied to user fee shortfall: CDRH's decision to exempt modular PMAs from user fees if the first module was submitted prior to Oct. 1, 2002 resulted in higher PMA costs for fiscal 2004, Director David Feigal tells attendees during the Regulatory Affairs Professionals Society's annual meeting in Baltimore Oct. 19-22. "Had we made the opposite decision on modular 510(k)s, we would have hit the [FY 2003] fees right on the nose," he notes. "One of the reasons we didn't raise $25 mil. and only raised $19 mil. [is that we had] 54 PMAs last year and there were also 22 modular PMAs in house." Standard PMA fees for FY 2004 will increase almost 35% to $206,811 (1"The Gray Sheet" Aug. 4, 2003, p. 3)...

You may also be interested in...



CBER Should Retain Jurisdiction of Assigned Device Reviews – HHS Report

Improved device review times, including speedy handling of West Nile Virus diagnostics, convinced HHS that the Center for Biologics Evaluation & Research should retain jurisdiction over blood and tissue-related devices already assigned to the center

CBER Should Retain Jurisdiction of Assigned Device Reviews – HHS Report

Improved device review times, including speedy handling of West Nile Virus diagnostics, convinced HHS that the Center for Biologics Evaluation & Research should retain jurisdiction over blood and tissue-related devices already assigned to the center

AdvaMed Seeks Additions To MDUFMA Reuse Lists, Criticizes Review Criteria

The Association of Medical Device Reprocessors will meet with FDA Sep. 12 to discuss the agency's validation guidance, according to AMDR reps

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel